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Abstract
Background: Lupus retinopathy is one of the most common vision-threatening complications of systemic lupus
erythematosus. The presence of lupus retinopathy is an accurate guide to the presence of active systemic disease
activity.
Results: A prospective study was conducted looking at 91 established cases of systemic lupus erythematosus to
evaluate lupus retinopathy. The patients were divided into two groups according to the presence or absence of
lupus retinopathy, and a comparison of clinical and laboratory findings between two groups was done. Among 91
SLE patients, 5 were male and 86 were female; of which, 85 (93.4 %) were outpatients and
6 (6.6 %) were inpatients. Lupus retinopathy was found in 13 eyes of 11 cases out of 91 cases (12.1 %). Among
these 13 eyes with lupus retinopathy, 61.5 % had mild type of lupus retinopathy, 15.4 % had moderate type, and
23.1 % had severe lupus retinopathy.
The mean age of the cases at ophthalmological examination with and without retinopathy was 30.4 and 31.9 years,
respectively. The mean serum creatinine level was 190.4 μmol/l which was higher than in the patients without
retinopathy (96.2 μmol/l). The mean ESR in patients with retinopathy was higher than without retinopathy (34.2
vs. 32). Similarly, the mean platelet count in SLE patients with retinopathy was 154,245/μl and in SLE patients
without retinopathy was 135,828/μl.
Conclusions: Retinal lesions in SLE patients are of critical importance, both visually and prognostically.
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Background
Systemic lupus erythematosus (SLE) is a chronic, auto-
immune, connective tissue disorder affecting multiple
organ systems often with a relapsing and remitting clinical
course. SLE is often called a “woman’s disease” because
90 % of affected individuals are females [1]. Manifestations
of SLE are protean and any organ or system of the body
including the eye can be affected due to the inflammatory
response to the circulating immune complexes [1].
Ocular manifestations are a marker for overall systemic
disease activity and can occur in up 1/3rd of all SLE
patients. The incidence of retinal involvement in SLE is
7–26 % [2] and is the second most common ocular mani-
festation after keratoconjunctivitis sicca [3]. It is one of
the most common vision-threatening complications of
systemic lupus erythematosus with an incidence of up to
29 % in patients with active systemic disease [3]. The pres-
ence of active SLE retinal vasculopathy is an extremely ac-
curate guide to the presence of systemic disease activity,
occult or overt. Additionally, life-table survival estimates
have shown decreased survival in patients with SLE ret-
inopathy, compared to SLE patients without retinopathy
[3]. Retinal lesions in SLE patients, therefore, are of critical
importance, both visually and prognostically [4].
The control of systemic SLE is the mainstay of treat-
ment for lupus retinopathy which can be achieved by sys-
temic corticosteroids and immunosuppression [3]. Initial
treatment is usually with oral corticosteroids (prednisol-
one 1 mg/kg/day), but may be preceded by intravenous
methylprednisolone (500 mg–1 g daily for 3 days).
This is then supplemented with, or replaced by, other
immunosuppressive agents as part of a steroid-sparing
strategy or for resistant disease [3]. Periocular steroid
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injections may have a role in unilateral/asymmetric
disease; however, they should be used cautiously and
avoided in patients with necrotising scleritis [2]. In the
presence of significant vaso-occlusive disease with the
presence of antiphospholipid antibody, anti-coagulation
and the addition of low-dose acetylsalicylic acid may be
beneficial [5]. Proliferative retinopathy usually requires
treatment with laser photocoagulation akin to the treat-
ment of proliferative diabetic retinopathy [6].
Methods
A prospective study was conducted among the established
cases of SLE referred to the eye department from the
various departments of Tribhuvan University Teaching
Hospital between 2008 and 2010. After dilated fundus
evaluation, presence or absence of lupus retinopathy was
identified and grading was done. Mild lupus retinopathy
consists of cotton–wool spots, perivascular hard exudates,
retinal hemorrhages, and vascular tortuosity [7]. Moderate
lupus retinopathy has focal or generalized arteriolar con-
striction and venous tortuosity. At the severe end of the
spectrum, there is occlusion of retinal arterioles and conse-
quent retinal infarction, termed vaso-occlusive retinopathy
[8] causing artery/vein occlusions, vitreous hemorrhage,
retinal ischemia, and neovascularisation [8–11].
The patients were divided into two groups according to
the presence or absence of lupus retinopathy, and a com-
parison of clinical and laboratory findings between two
groups was done. Patients were followed up for 2 years.
Patients
Ninety-one consecutive patients with SLE (5 male, 86
female) who fulfilled the American College of Rheuma-
tology criteria for SLE [11] were enrolled; 85 outpatients
(93.4 %) and six were inpatients (6.6 %). The mean age
of female and male cases at the ophthalmological exami-
nations were 26.7 (SD ± 10.3) years and 24.4 (SD ± 12.1)
years, respectively.
Thirty-one patients (34.1 %) were receiving corticoste-
roids; 30 patients (32.96 %) were treated with combin-
ation of corticosteroid with antimalarial (14.3 %) and/or
antihypertensive agents (12.1 %). Intravenous methyl-
prednisolone was administered in four cases (4.4 %). The
mean duration of steroid treatment was 2.1 years. The
daily dose of oral corticosteroid at the ophthalmological
examination ranged between 10 and 40 mg.
Nine patients (9.9 %) were under immunosuppressant
drugs, including cyclophosphamide and azathioprine; six
patients (6.6 %) with CNS involvement were under anti-
epileptics. However, 20 patients (21.9 %) were without
any medication as they were referred to the eye depart-
ment to rule out any contraindication before starting
hydroxychloroquine.
Statistical analysis
The data were analyzed with SPSS 20 version, and t test
and Fisher’s 2 × 2 test were used to analyze p value.
Results
A total of 91 SLE patients (182 eyes) were examined to
evaluate the presence of lupus retinopathy.
Incidence and features of lupus retinopathy
Lupus retinopathy was found in 11/91 (12.1 %) patients
with female to male ratio of 10:1. The mean age of the
cases at ophthalmological examination with and without
retinopathy was 30.4 and 31.9 years, respectively.
Among them, eight cases (72.7 %) were examined in outpa-
tients settings and three (27.3 %) were indoor cases (Table 1).
Among the cases with retinopathy, nine patients had
unilateral retinopathy and two patients had bilateral lupus
retinopathy. The mean IOP was normal.
Table 2 Backgrounds of the retinal findings in SLE
Retinal findings in SLE




















7a + + +
8 + +
9 + +
10a + + +
11 + +
aIn two patients, one eye had cotton–wool spot with hard exudates and the
other eye had arteriolar attenuation




Number of SLE patients 80 11
Number of SLE admitted cases 6/91 (6.6 %) 3/11 (27.3 %)
Age at onset of SLE (years) 31.9 30.4
Oral Steroid dose at ophthalmological
examination (range)
5–50 mg 10–40 mg
History of intravenous steroid 3/91 (3.3 %) 1/11 (9.1 %)
History of immunosuppressant treatment 8/91 (8.8 %) 1/11 (9.1 %)
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Retinal findings of the patients with lupus retinopathy
(Table 2)
Among these 13 eyes of 11 patients of lupus retinopathy,
commonest was the mild type in eight eyes (61.5 %)
followed by moderate type in two eyes (15.4 %) and severe
type in three eyes (23.1 %). Among severe lupus retinop-
athy, two eyes had retinal vasculitis and one eye had cen-
tral retinal arterial occlusion (CRAO).
Systems affected in SLE retinopathy (Table 3)
In our 91 SLE patients, renal involvement was found in
59.3 % cases and central nervous system in 11 %. But in
those 11 cases with lupus retinopathy, 100 % renal and
27.3 % central nervous system involvement was found.
So, all our cases of lupus retinopathy had renal dysfunc-
tion in the form of protenuria or a raised creatinine
level. The CNS findings observed in lupus retinopathy
cases were chorea, convulsion, and epilepsy.
The mean serum creatinine level was 190.4 μmol/l
which was higher than in the patients without retinopathy
(96.2 μmol/l). The mean ESR in patients with retinopathy
was higher than without retinopathy (34.2 vs. 32). Similarly,
the mean platelet count in SLE patients with retinopathy
was 154,245/μl and in SLE patients without retinopathy
was 135,828/μl (Table 4).
Association with autoantibodies
SLE is generally considered to be an immune complex-
mediated disease where the lupus retinopathy occurs due
to immune complex deposition in retinal vessels in SLE
[12]. The incidence of antinuclear antibody (ANA) and
anti-dsDNA antibody in SLE patients with retinal vascular
disease versus without retinal vascular disease was 87.5
and 72.7 %. The higher positive antiphospholipid anti-
bodies were seen in SLE patients in those with retinopathy
compared to those without retinopathy was 18.1 versus
4.4 %. But all of them were not statistically significant.
Discussion
Retinopathy is one of the important manifestations of
SLE, which develops with an incidence of 7–26 % [4] of
SLE patients, although the frequency of the findings
varies depending on the patient population being stud-
ied and systemic disease activity [12]. According to
Ushiyama et al. [13], the incidence of lupus retinopathy
is 10 % (7/69) which is similar to our incidence of lupus
retinopathy {12.1 % (11/91)}. Our study reveals inci-
dence of lupus retinopathy in admitted patients to be
27.3 % which correlated with the other literature where
lupus retinopathy in the admitted patients could be as
high as 29 % [14].
Ushiyama et al. [13] reported the mean age at onset of
SLE in the patients with and without retinopathy to be
34.2 and 31.9 years, respectively, and all of them were
females. This is comparable with our study where the
mean ages at onset of SLE in our patients were 30.4 and
31.9 years, respectively, of them, 10 were females and 1
male. Sex hormones are known to affect the clinical
course of SLE; estrogen enhances the disease and testos-
terone suppresses it [15, 16] and 90 % of women are of
child-bearing age [17].
Retinopathy in SLE is suggestive of high disease activity
during the course of SLE, and hence, is a marker of poor
prognosis for survival, that is SLE patients with retinop-
athy have overall worse prognosis and decreased survival,
compared to SLE patients without retinopathy [3]. Inter-
estingly, the severe form of vaso-occlusive retinopathy is
associated with similar changes in the central nervous sys-
tem vasculature [8, 18, 19].
We found that the renal dysfunction in SLE without
retinopathy was 59.3 %, but in patients with retinopathy
Table 4 Comparison of significance test in SLE with or without retinopathy
SLE without retinopathy SLE with retinopathy Remarks on p value
Renal system involvement 54/91 (59.3 %) 11/11 (100 %) 0.003 (p value statistically significant)
CNS involvement 10/91 (11 %) 3/11 (27.3 %) .347
Mean ESR 32.03 34.18 .660
Mean platelet count (per μl) 135,828 154,245 .649
Mean serum creatinine (μmol/l) 96.2 μmol/l 190.4 μmol/l .001 (p value statistically significant)
Table 3 Systemic involvement in lupus retinopathy
Patient
no.




1 F/54 LE mild retinopathy + –
2 F/24 RE mild retinopathy + –
3 F/40 RE severe retinopathy + –
4 F/42 LE severe retinopathy + –
5 F/27 BE mild retinopathy + +
6 F/44 RE mild retinopathy + −
7 F/30 RE mild and LE moderate
retinopathy
+ +
8 M/13 RE mild retinopathy + −
9 F/22 RE mild retinopathy + −
10 F/24 RE moderate and LE mild
retinopathy
+ +
11 F/26 RE mild retinopathy + −
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was 100 %. Although it is unclear whether lupus retinop-
athy is directly associated with renal disease, retinopathy
may develop in severe SLE which also involves the kidney
or CNS, or both. It has a major impact on morbidity and
mortality.
Several studies report that retinal vascular disease in
SLE patient parallels systemic disease activity [14, 20]
and that the effective treatment of the systemic disease,
along with simultaneous control of any associated sys-
temic hypertension, results also in concurrent decrease in
the retinal lesions, especially the disappearance of cotton–
wool spots [9, 14].
The serologic hallmark of SLE is the presence of ANAs
in highly sensitive and useful screening tool. Anti-dsDNA
antibody is SLE specific and correlates with disease activity
[21]. The antiphospholipid antibody is thrombogenic and
is associated with both CNS and ocular vaso-occlusive
phenomena [18] that can manifest as visual disturbances,
transient monocular blindness, and chorioretinopathy in
patients with SLE [22]. A higher incidence of antiphospho-
lipid antibodies in SLE patients with retinal vascular dis-
ease, compared to those without (77 vs. 29 %), has been
reported [23] and in our study also the incidence was 18.1
versus 4.4 %.
Conclusions
The ocular fundus is the only part of the human body
where we can directly observe small vessels without in-
juring the tissue. And lupus retinopathy reflects systemic
vascular damage, so ocular fundus examination should
be regularly done. Finally, the eyes may be the harbinger
of a potentially severe systemic flare-up of SLE, so careful
monitoring is needed. A symbiotic relationship among
rheumatologist, physicians, dermatologist, and ophthal-
mologist may be formed to better understand the disease
status and plan the treatment strategy of the patients with
SLE.
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